Your session is about to expire
← Back to Search
VIB4920 for Lupus Nephritis (VIBRANT Trial)
VIBRANT Trial Summary
This trial is testing a new drug to see if it's effective in treating lupus nephritis, a kidney disease. The trial is double-blind, meaning neither the patients nor the doctors know who is receiving the real drug or the placebo.
VIBRANT Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowVIBRANT Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2023 Phase 2 trial • 25 Patients • NCT04046549VIBRANT Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have been diagnosed with Systemic Lupus Erythematosus.I am unwilling to use birth control.I have previously been treated with VIB4920.I haven't taken any biologic treatment recently, except for belimumab.You are currently using drugs or have used drugs in the past year.I frequently get serious infections.I have not received a live vaccine in the last 4 weeks.You had a kidney biopsy within the last 24 weeks and it showed specific criteria.You don't have a vein that can be used for taking blood from your arm.I have not received Rituximab or similar treatments in the last 6 months.I am at risk for blood clots.I have had tuberculosis in the past or have it now.I do not have any ongoing serious infections.I have or had hepatitis B.You have any of the listed abnormal test results.Your UPCR (urine protein-to-creatinine ratio) is higher than 1.0 based on a 24-hour urine collection before the study starts.You have had a serious mental health condition in the past.You have had an organ or tissue transplant in the past.I have or had hepatitis C.I am HIV positive.I have other health issues not mentioned here.I cannot take MMF or mycophenolate sodium due to health reasons.I am 18 years old or older.I am being treated with steroids for another health condition.My kidneys are in the final stage of failure.I have a history of cancer, but it may fit exceptions.
- Group 1: VIB4920 Placebo
- Group 2: VIB4920
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there any deleterious effects associated with VIB4920 usage?
"The safety of VIB4920 has been assessed with a score of 2 since clinical data verifies its security, although the drug's efficacy has yet to be established."
How many locations in the city are implementing this research experiment?
"There are 15 locations enrolling patients in this trial, such as the University of Miami Miller School of Medicine: Nephrology & Hypertension Division (Miami), Washington University School of Medicine in St. Louis: Division of Nephrology (St. Louis) and the University of California San Diego School of Medicine: Division of Rheumatology, Allergy and Immunology (La Jolla). Additionally, there are a dozen other medical centers taking part in this study."
How many participants are included in the current clinical trial?
"Affirmative. According to clinicaltrials.gov, this project is actively seeking eligible participants after being first posted on May 16th 2022 and recently updated on November 21st 2022. A total of 114 individuals are required for the study at 15 different medical locations."
Are new participants being admitted to this investigation?
"Clinicaltrials.gov shows that recruitment for this medical trial is still ongoing, with the initial posting occurring on May 16th 2022 and most recent update taking place November 21st of the same year."
Who else is applying?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Share this study with friends
Copy Link
Messenger